Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Segment Results
MDT logo

Medtronic Posts 7% Q2 Sales Growth on Innovation and Organic Momentum

MDT10-QFiling Date: 11/25/2025
Medtronic plc
Description

What this story covers

Medtronic's Q2 FY2026 10-Q shows 7% net sales growth to $8.961B, driven by Cardiovascular and Diabetes segments amid currency tailwinds. Organic growth at 5%, margins expand to 19% adjusted. Robust liquidity supports Diabetes spin-off, with 4.5-5.5% FY outlook despite legal risks and tariffs. Focus on high-acuity therapies ensures resilience.

Story snapshot

CompanyMedtronic plc
TickerMDT
VariantStandard detailed
Duration14:52
Filing type10-Q
PeriodQ2 2026
IndustryHealthcare & Pharmaceuticals
Accession0001628280-25-053988

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in